Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Albumin Levels on Pharmacokinetics of Cefazolin in Adult Cardiac Surgery
2024-518338-10-00Phase 4Authorised
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of cefazolin and albumin (human) in cardiac disease and hypoalbuminemia (2 arms), sponsored by Medical University of Vienna. Primary endpoint: AUC0-10 for free and total cefazolin. Planned start Dec 2024; status: authorised.
02
Drugs
cefazolinalbumin (human)
03
Conditions
cardiac diseasehypoalbuminemia
Beyond the preview
Go deeper on 2024-518338-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518338-10-00.